SNAC semaglutide: how the Wegovy tablet gets absorbed

Why does semaglutide need SNAC in the first place?

Semaglutide is a peptide (a small protein) and the digestive system is remarkably good at breaking peptides apart. Swallow semaglutide alone and stomach acid degrades most of it before it reaches the tissue that would absorb it. SNAC changes that picture. It is a medium-chain fatty acid salt that temporarily raises the pH immediately around the tablet, protecting semaglutide in a localised pocket of lower acidity, and at the same time makes the cells lining the stomach wall more permeable to the molecule. The result is a narrow but reliable absorption window, enough for clinically meaningful blood levels.

This mechanism is well-established for oral semaglutide in the diabetes context (Rybelsus uses the same SNAC technology at lower doses for type 2 diabetes) but the Wegovy tablet is a different product, licensed at higher doses specifically for weight management. The distinction matters: Rybelsus is not a weight-loss medicine, and the two should never be used interchangeably. The full Wegovy guide on our site covers how the injection and tablet compare.

Because absorption depends so precisely on this SNAC mechanism, the tablet's taking instructions are strict in a way that the injection's are not. Understanding the chemistry makes those instructions feel less arbitrary.

What do the trial results show for SNAC semaglutide used for weight loss?

The pivotal evidence comes from OASIS 4, a phase 3 trial of 307 adults with obesity or overweight plus at least one weight-related condition, running for 64 weeks alongside lifestyle changes. Average weight loss across the whole treatment group was around 13.6%, compared with roughly 2.4% in the placebo group. Among participants who adhered fully to the tablet's taking requirements throughout the trial, the average loss was closer to 17%. That second figure is meaningful but conditional, it describes a specific subset, not the trial population as a whole, so it is important not to read it as a flat average.

For context, the weekly semaglutide injection (Wegovy 2.4 mg) showed around 15% average weight loss over 68 weeks in the STEP 1 trial, as reported in the New England Journal of Medicine. The tablet's results sit below that on a straight comparison, though direct head-to-head data in the same trial are not yet available. Both remain clinically substantial figures. What the tablet offers is not necessarily superior weight loss but a different format, no injections, no refrigeration, no sharps disposal.

The most commonly reported side effects in OASIS 4 were gastrointestinal: nausea, vomiting, diarrhoea and constipation, occurring in the majority of participants on active treatment. These were generally mild to moderate and most pronounced when starting or increasing the dose. The NHS semaglutide medicines page sets out the full side-effect profile in patient-friendly terms and is worth reading before starting treatment.

How should the tablet be taken to make the SNAC mechanism work?

This is where the oral route asks something specific of patients that the injection does not. The tablet should be taken first thing in the morning, on an empty stomach, with a small amount of plain water, no more than about 120 ml. Crucially, you should then wait at least 30 minutes before eating, drinking anything else (including coffee or tea), or taking other oral medicines. Swallow the tablet whole; crushing or chewing it disrupts the SNAC delivery system.

A practical check worth building into your morning: put the tablet on the kitchen counter the night before, next to a measured glass of water, and set a 30-minute timer on your phone after you take it. That one habit, replicated consistently, is the single biggest thing you can do to protect bioavailability. People who have been on the 2.4 mg weekly injection may move directly to the 25 mg tablet under clinical guidance, without repeating the full dose-escalation ladder from 1.5 mg, but this is always a prescriber decision, not a self-directed switch. You can read more about how semaglutide works on our dedicated page.

Storage is genuinely simpler than the injection. The tablet is kept at room temperature, needs no cold chain and is not affected by the storage windows that govern the pen. For people who travel frequently or find fridge management inconvenient, that is a real practical difference. Details on the exact storage conditions sit in the patient information leaflet that comes with every pack, the leaflet is the authoritative reference, not summaries elsewhere.

Who is currently eligible for the Wegovy tablet, and what does the NHS position look like?

The MHRA licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. The tablet is not licensed for people under 18, and it is not recommended during pregnancy, breastfeeding or when trying to conceive, a prescriber will discuss these points as part of clinical assessment.

The NHS position at launch is that the Wegovy tablet is not available through the NHS; a NICE appraisal would need to take place before that could change. That means private prescription is the only current legal route. Semaglutide dosing questions come up frequently in consultations, and our prescribers review each case individually, no algorithm does that work. For those weighing up the cost of private treatment, the Wegovy price comparison page explains what legitimate private pricing typically includes and why headline figures can be misleading. If you are already exploring your options more broadly, and would like to understand how semaglutide 2 fits into the wider picture, the treatment overview sets out everything currently available through nume.

The tablet's approval is recent enough (June 2026) that clinical familiarity is still building across UK healthcare. The MHRA's published announcements on semaglutide approvals remain the most authoritative public record of what is and is not licensed. If you would like a prescriber to assess whether the caneta Wegovy tablet is appropriate for you, checking your eligibility through a free consultation is the place to start.